Nurix Therapeutics reported revenue of $9.04M and net income of -$89.53M for the quarter ended May 2026, down 79.5% year over year. This income statement covers 28 quarters of results from Aug 2019 through May 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Aug2019 | Nov2019 | Feb2020 | May2020 | Aug2020 | Nov2020 | Feb2021 | May2021 | Aug2021 | Nov2021 | Feb2022 | May2022 | Aug2022 | Nov2022 | Feb2023 | May2023 | Aug2023 | Nov2023 | Feb2024 | May2024 | Aug2024 | Nov2024 | Feb2025 | May2025 | Aug2025 | Nov2025 | Feb2026 | May2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | ||||||||||||||||||||||||||||
| Revenue | 10.25M | 7.40M | 9.62M | 11.43M | 10.79M | 6.78M | 12.69M | 30.68M | 18.47M | 15.16M | 16.59M | 12.09M | 12.59M | 13.28M | 18.45M | 44.06M | 7.89M | 13.58M | 6.25M | 9.04M | ||||||||
| Operating items | ||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 30.91M | 36.53M | 43.14M | 47.49M | 47.76M | 46.11M | 45.82M | 45.76M | 47.86M | 49.71M | 50.01M | 48.92M | 55.48M | 67.22M | 69.66M | 78.10M | 86.12M | 83.02M | 84.14M | 87.65M | ||||||||
| Selling, General & AdministrativeSG&A | 8.34M | 8.82M | 9.23M | 9.65M | 9.75M | 9.37M | 9.82M | 11.68M | 10.62M | 10.78M | 11.80M | 11.71M | 11.72M | 10.72M | 11.65M | 14.28M | 13.16M | 13.65M | 14.61M | 15.59M | ||||||||
| Operating ExpensesOpex | 39.25M | 45.35M | 52.37M | 57.15M | 57.51M | 55.47M | 55.64M | 57.44M | 58.48M | 60.49M | 61.80M | 60.63M | 67.20M | 77.94M | 81.32M | 92.38M | 99.28M | 96.67M | 98.75M | 103.25M | ||||||||
| Operating IncomeOp. Inc | -29.00M | -37.95M | -42.74M | -45.72M | -46.72M | -48.69M | -42.95M | -26.77M | -40.01M | -45.33M | -45.22M | -48.54M | -54.61M | -64.66M | -62.86M | -48.32M | -91.39M | -83.09M | -92.50M | -94.20M | ||||||||
| EBIT | -29.00M | -37.95M | -42.74M | -45.72M | -46.72M | -48.69M | -42.95M | -26.77M | -40.01M | -45.33M | -45.22M | -48.54M | -54.61M | -64.66M | -62.86M | -48.32M | -91.39M | -83.09M | -92.50M | -94.20M | ||||||||
| Non-operating items | ||||||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.04M | 0.29M | 0.21M | 0.31M | 1.01M | 1.97M | 2.22M | 2.49M | 3.03M | 3.38M | 3.79M | 4.08M | 5.74M | 6.12M | 6.51M | 5.62M | 4.96M | 4.87M | 5.32M | 4.40M | ||||||||
| Net income details | ||||||||||||||||||||||||||||
| EBT | -28.96M | -37.66M | -42.53M | -45.40M | -45.71M | -46.72M | -40.73M | -24.28M | -36.98M | -41.96M | -41.43M | -44.46M | -48.87M | -58.54M | -56.35M | -42.70M | -86.42M | -78.22M | -87.17M | -89.81M | ||||||||
| Tax ProvisionsTaxes | -0.12M | 0.03M | 0.09M | 0.09M | 0.08M | 0.01M | 0.76M | -0.27M | ||||||||||||||||||||
| Profit After TaxPAT | -28.84M | -37.70M | -42.53M | -45.40M | -45.71M | -46.72M | -40.73M | -24.28M | -36.98M | -41.96M | -41.52M | -44.55M | -48.96M | -58.55M | -56.35M | -43.46M | -86.42M | -78.22M | -87.17M | -89.53M | ||||||||
| Income from Continuing OperationsIncome (Continuing) | -28.84M | -37.69M | -42.53M | -45.40M | -45.71M | -46.72M | -40.73M | -24.28M | -36.98M | -41.96M | -41.52M | -44.55M | -48.96M | -58.55M | -56.35M | -43.46M | -86.42M | -78.22M | -87.17M | -89.53M | ||||||||
| Consolidated Net IncomeConsol Net Inc. | -28.84M | -37.69M | -42.53M | -45.40M | -45.71M | -46.72M | -40.73M | -24.28M | -36.98M | -41.96M | -41.52M | -44.55M | -48.96M | -58.55M | -56.35M | -43.46M | -86.42M | -78.22M | -87.17M | -89.53M | ||||||||
| Income towards Parent CompanyParent Net Inc | -28.84M | -37.69M | -42.53M | -45.40M | -45.71M | -46.72M | -40.73M | -24.28M | -36.98M | -41.96M | -41.52M | -44.55M | -48.96M | -58.55M | -56.35M | -43.46M | -86.42M | -78.22M | -87.17M | -89.53M | ||||||||
| Net Income towards Common StockholdersNet Income | -28.84M | -37.69M | -42.53M | -45.40M | -45.71M | -46.72M | -40.73M | -24.28M | -36.98M | -41.96M | -41.52M | -44.55M | -48.96M | -58.55M | -56.35M | -43.46M | -86.42M | -78.22M | -87.17M | -89.53M | ||||||||
| Additional items | ||||||||||||||||||||||||||||
| EPS (Basic) | -0.65 | -0.88 | -0.95 | -1.01 | -0.90 | -0.96 | -0.75 | -0.45 | -0.68 | -0.77 | -0.76 | -0.71 | -0.67 | -0.87 | -0.67 | -0.52 | -1.03 | -0.90 | -0.79 | -0.81 | ||||||||
| EPS (Diluted) | -0.65 | -0.88 | -0.95 | -1.01 | -0.90 | -0.96 | -0.75 | -0.45 | -0.68 | -0.77 | -0.76 | -0.71 | -0.67 | -0.87 | -0.67 | -0.52 | -1.03 | -0.90 | -0.79 | -0.81 | ||||||||
| Shares Outstanding | 44.37M | 42.90M | 44.69M | 44.90M | 50.87M | 48.61M | 54.03M | 54.26M | 54.39M | 54.34M | 54.90M | 62.38M | 72.78M | 67.12M | 83.56M | 83.88M | 84.16M | 86.67M | 110.07M | 111.08M | ||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 44.37M | 42.90M | 44.69M | 44.90M | 50.87M | 48.61M | 54.03M | 54.26M | 54.39M | 54.34M | 54.90M | 62.38M | 72.78M | 67.12M | 83.56M | 83.88M | 84.16M | 86.67M | 110.07M | 111.08M | ||||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 44.56M | 44.66M | 44.85M | 45.04M | 47.15M | 47.17M | 47.44M | 47.63M | 48.50M | 48.72M | 49.14M | 64.36M | 67.08M | 75.87M | 76.23M | 76.43M | 76.87M | 101.81M | 103.40M | 103.70M | ||||||||
| EBITDA | -29.00M | -37.95M | -42.74M | -45.72M | -46.72M | -48.69M | -42.95M | -26.77M | -40.01M | -45.33M | -45.22M | -48.54M | -54.61M | -64.66M | -62.86M | -48.32M | -91.39M | -83.09M | -92.50M | -94.20M | ||||||||
| Tax Rate | 0.42% | -0.08% | -0.22% | -0.20% | -0.17% | -0.01% | -1.78% | 0.30% |